5-Fluorouracil and High-Dose Calcium Leucovorin for Hepatocellular Carcinoma: A Phase II Trial
作者:
TetefMerry,
DoroshowJames,
AkmanSteven,
ColuzziPaul,
LeongLucille,
MargolinKim,
MorganRobert J.,
RaschkoJames,
ShibataStephen,
SomloGeorge,
AhnChul,
期刊:
Cancer Investigation
(Taylor Available online 1995)
卷期:
Volume 13,
issue 5
页码: 460-463
ISSN:0735-7907
年代: 1995
DOI:10.3109/07357909509024907
出版商: Taylor&Francis
数据来源: Taylor
摘要:
A phase II trial of 5-fluorouracil (5-FU) [250450 mg/m2/day×5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day×5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma. The median age was 58 years; performance status ranged from 50 to 100%. Of 15 evaluable patients, 1 (7%) had a partial response lasting 2.4 months; 8 (53%) had stable disease with a median duration of 5.7 months; and 6 (40%) had progressive disease with a median time to progression of 2.7 months. Median survival was 3.8 months. Treatment with 5-FU and calcium leucovorin was moderately well tolerated; 9% of the treatment courses were complicated by grade 3 or 4 hematological toxicity, and 10% of the courses were complicated by grade 3 or 4 gastrointestinal toxicity. Despite the efficacy of the combination of 5-FU and leucovorin in advanced colorectal cancer, our results document the general resistance of hepatocellular carcinoma to modulated 5-FU.
点击下载:
PDF (307KB)
返 回